| Name | Title | Contact Details |
|---|
DNA Script was created to revolutionize DNA synthesis with enzymes` Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation` The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology` With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine`
Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient`s body.
Marsh is a global leader in insurance broking and risk management. Marsh helps clients succeed by defining, designing, and delivering innovative industry-specific solutions that help them effectively manage risk. Marsh’s approximately 26,000 colleagues work together to serve clients in more than 130 countries. Marsh is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC), a global professional services firm offering clients advice and solutions in the areas of risk, strategy, and human capital. With 55,000 employees worldwide and annual revenue exceeding $12 billion, Marsh & McLennan Companies is also the parent company of Guy Carpenter, a global leader in providing risk and reinsurance intermediary services; Mercer, a global leader in talent, health, retirement, and investment consulting; and Oliver Wyman, a global leader in management consulting.
Tarcine is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.